14 August 2025; Company Announcement Full-Year Results 2024-25 – Acrobat pdf 364k
Highlights
- Revenue from ordinary activities $213.0m – up 31.9%
- Underlying profit before tax $163.3m – up 40.2%
- Net profit $115.2m – up 39.2%
- Cash and other financial assets $210.7m – up 35.5%
- Company remains debt-free
- Record year for new contract wins, contract renewals and sale of additional modules to existing clients.
- Fully-franked final dividend 30c per share
Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a full-year net profit of $115.2 million for the twelve months to the end of June 2025, 39.2% higher than the previous corresponding period.
Revenue from ordinary activities was $ 213.0 million, up 31.9%.
The company’s cash and other financial assets at the end of June 2025 were $210.7 million, an increase of 35.5%.
Pro Medicus announced a fully-franked final dividend of 30c per share. The company remains debt-free.
Revenue increased in all key jurisdictions: North America up 35.8%, Australia up 4.9% and Germany up 8.6%.
During the year Pro Medicus announced $520 million in new contracts, including:
- A $330 million, ten-year contract with Trinity Health, one of the largest not-for-profit health care systems in the United States.
- A $30 million, 7-year contract with Duly Health and Care, the largest independent, multi-specialty physician-directed medical group in the USA Midwest.
- A $33 million, 9-year contract with University of Kentucky, the preeminent academic health system in Kentucky.
- A $5 million, 7-year contract with Lurie Children’s Hospital, a nationally ranked paediatric acute care children’s hospital in Chicago.
- A $53 million, 7-year contract with BayCare, the leading health care system in the Tampa Bay and central Florida regions of the USA.
- A $40 million, 7-year contract with Lucid Health, a leading provider of radiology services in the USA.
- A $20 million, 5-year contract with the University of Iowa Health Care, Iowa’s comprehensive academic health system.
The company also announced $130 million in contract renewals during the year, including:
- A $98 million 8-year contract with St Louis-based Mercy Health, a healthcare network with more than 40 acute care and specialty hospitals.
- A $32 million 5-year contract with a large Australian radiology network.
In addition, Pro Medicus announced the upgrades to existing contracts with clients NYU Langone ($24 million over 5 years) and Duke Health ($15 million over 5 years).
Dr Sam Hupert, CEO of Pro Medicus, said the year represented a record year for the company in terms of revenue, net profit, sales and implementations. “All key Financial metrics headed in the right direction,” he said. “And, importantly we continued our trajectory of strong, profitable growth.”
Dr Hupert said Pro Medicus’ sales during the year will set the company up for the FY26 year and beyond. “The majority of the contracts that we signed were in the second half of the year and will come on stream this coming year and beyond, so there is a very sizeable revenue pathway in front of us,” he said. “It was also a strong year for implementations as we were able to complete 7 implementations including Baylor, Scott and White which we completed in a three-month window. We now have around 10% of the total addressable market in the USA which is material, but it also means there is plenty of scope for further growth.”
Post 30th of June, the company also signed the following two contracts:
- A $170 million 10-year contract with UCHealth, including the Visage 7 Cardiology offering.
- A $20 million 5-year renewal contract with Franciscan Missionaries of Our Lady Health System, including Visage 7 Open Archive in the cloud.
Dr Hupert said more clients were opting to buy Pro Medicus’ full-stack – Viewer, Archive and Workflow Management and that fully cloud based implementations were now becoming the norm.
“We continue to see Cloud as a strategic advantage for us, as our competition has not been able to re-engineer their systems to fully take advantage of cloud and have had to resort to hybrid options which we feel is a backward step.”
Commenting on the pipeline, Dr Hupert said “Whilst we have had an unprecedented year in terms of converting opportunities in the pipeline to sales, our pipeline remains strong with new opportunities spanning all key market segments including Academic Medical Centres, IDNs and the private market.”
